Xu, Q., Liu, H., Meng, S., Jiang, T., Li, X., Liang, S., . . . Zhou, C. (2019). First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer.

Xu, Qinghua, Hui Liu, Shuyan Meng, Tao Jiang, Xuefei Li, Shixiong Liang, Shengxiang Ren, and Caicun Zhou. "First-line Continual EGFR-TKI Plus Local Ablative Therapy Demonstrated Survival Benefit in EGFR-mutant NSCLC Patients With Oligoprogressive Disease." J Cancer 2019.

Xu, Qinghua, et al. "First-line Continual EGFR-TKI Plus Local Ablative Therapy Demonstrated Survival Benefit in EGFR-mutant NSCLC Patients With Oligoprogressive Disease." J Cancer 2019.